Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance
NCT ID: NCT04566055
Last Updated: 2020-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2019-03-01
2020-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry
NCT03326076
AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
NCT04057742
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
NCT07060716
Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients.
NCT04855422
ddcfDNA in Kidney Transplant Recipients
NCT06013358
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prospective observational cohort
AlloSure
Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AlloSure
Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
12 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CareDx
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Hospital
Aurora, Colorado, United States
Tampa General Hosptial
Tampa, Florida, United States
University of Maryland
Baltimore, Maryland, United States
University of Minnesota Medical Center
Minneapolis, Minnesota, United States
Washington University
St Louis, Missouri, United States
Memorial Hermann Hosptial
Houston, Texas, United States
Intermountain Medical Center
Murray, Utah, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADMIRAL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.